Non-invasive follicular neoplasm with papillary-like nuclear features: a challenging and infrequent entity in Argentina

Melina Sabán 1 · Norma Tolaba 2 · Ana María Orlandi 3 · Susana Deutsch 4 · Fabián Pitoia 5 · Alicia Lowenstein 6 · María Cristina Calabrese 7 · Andrea Cavallo 8 · Alejandro Iotti 1 · Marcelo Monteros Alvi 2 · Marcelo Nallar 2 · Ana Jaén 9 · Silvina Figurelli 4 · Fernando Carrizo 10 · Antonio Colobraro 6 · Gabriela García Tascón 3 · María Saccoliti 7 · Andrea Paes de Lima 5 · Melisa Lencioni 8 · Inés Califano 10 · Carmen Cabezón 9 · on behalf of the Thyroid Department of Sociedad Argentina de Endocrinología y Metabolismo

Received: 7 February 2022 / Accepted: 12 June 2022 / Published online: 7 July 2022 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract

Purpose Non-invasive encapsulated follicular variant of papillary thyroid cancer was reclassified as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). These neoplasms have an extremely low malignant potential. The aim of this study was (1) to assess the prevalence of NIFTP in patients with papillary thyroid carcinoma, (2) to evaluate their outcomes, and (3) to determine their molecular profile.

Methods Multicenter, descriptive, retrospective study. Patients with papillary thyroid cancer diagnosed from January 2006 to December 2016 from 11 referral centers were included. Diagnosis of NIFTP was based on criteria described by Nikiforov et al. in 2018. At least two pathologists agreed on the diagnosis. Two thousand six hundred and seventy-seven papillary thyroid cancer patients were included; 456 (17%) of them were follicular variant papillary thyroid cancer, and 30 (1.12%) fulfilled diagnostic criteria for NIFTP.

Results Each of the 30 included patients underwent a total thyroidectomy, and 50% were treated with radioiodine (median dose 100 mCi). After a median follow-up of 37 months, 84% of patients had an excellent response, 3% had an indeterminate response and data was missing in the remaining 13%. No metastatic lymph nodes, distant metastases or recurrences were found. RAS mutations were detected in 4 patients (13%).

Conclusion The prevalence of NIFTP in our series is amongst the lowest reported. Excellent outcomes of patients underscore their low malignant potential. Molecular findings differ from other series, probably related to environmental or ethnic features of our population and the meticulous criteria for diagnosing NIFTP.

Keywords NIFTP · Follicular variant of papillary thyroid cancer · Thyroid neoplasm · Molecular analysis

Introduction

Follicular variant of papillary thyroid carcinoma (FVPTC) was described in 1977, as a tumor composed by neoplastic follicles with cells showing nuclear features characteristics of papillary thyroid cancer (PTC) [1, 2]. According to the...
Over the last decades, FVPTC incidence increased to comprise 10–20% of all differentiated thyroid cancer [4]. Encapsulated, non-invasive variant of FVPTC has an indolent biology, which led to an international expert panel (composed of pathologists, endocrinologists, surgeons) to reassess the features of this neoplasm aiming to establish and standardize diagnostic criteria and nomenclature which would better reflect clinical and biological characteristics of this tumor [1]. After this meeting, it was reclassified as non-invasive follicular neoplasm with papillary-like nuclear features (NIFTP). This new designation aimed to promote a more conservative treatment for these patients, to avoid the psychological burden of a cancer diagnosis and to reduce management associated costs [1].

Subsequently, several publications confirmed the indolent clinical course of NIFTP, its very low risk of recurrence and nearly non-existent risk of mortality [5].

Diagnosis of NIFTP is based on specific histomorphologic features, such as the presence of a capsule or a clearly delimited nodule, a follicular growth pattern and the nuclear features found in PTC. Invasion of the capsule and other exclusion criteria should be carefully ruled out [6]. In 2018, the diagnostic criteria for NIFTP were modified establishing that no true papillary structures should be present, and that if molecular studies were performed, high-risk alterations (i.e.: BRAF V600E and TERT mutations or RET/PTC rearrangements) should be absent, as well [6].

The aim of this study was (a) to retrospectively assess the prevalence of NIFTP on a population of PTC patients, (b) to describe their clinical and cytological characteristics (c) to determine their outcomes, and (d) to evaluate the molecular profile found in this neoplasm.

Materials and methods

A multicenter, observational study was performed. Patients older than 18 years, treated in eleven centers from Argentina, from January 2006 to December 2016 were included. Slides from 2677 patients with PTC diagnosis were reviewed; among them, 456 (17%) were FVPTC. These 456 histopathological samples were re-examined by at least two experienced pathologists from different centers. Clinical records were also reviewed to determine: cytological reports, type of initial surgery, treatment with radioiodine, initial response to treatment and the outcomes at the end of follow-up.

Inclusion criteria

NIFTP was diagnosed according to criteria defined by Nikiforov et al. [6] and it was confirmed by at least two pathologists. Criteria required for diagnosis were encapsulation or clear demarcation, a follicular growth pattern (no true papillary structures, no psammoma bodies, <30% solid/trabecular/insular growth pattern), and a nuclear score 2–3b.

Exclusion criteria

were presence of BRAF V600E mutation detected by molecular assays or immunohistochemistry (if molecular testing was performed), true papillae, psammoma bodies, lympho-vascular or capsular invasion, tumoral necrosis, high mitotic activity, cytologic/morphologic characteristics corresponding to other variants of PTC or poorly differentiated thyroid cancer.

Molecular analysis

For the evaluation of molecular alterations, a panel assessing 6 genes was performed in 19 of de 30 patients with NIFTP diagnosis (63%): mutations in BRAF (exon 15), K/H/N-RAS (exons 2 and 3), RET/PTC1 and PAX8/PPAR-Gamma fusions. DNA purification from paraffin blocks was optimized with High Pure PCR Template Preparation KIT (Roche); RNA was purified with a modified protocol of TRIzol (TriPure Isolation Reagent). Point mutations were studied with RT qPCR followed by high-resolution melting (HRM). Analysis of HRM was performed comparing curves of positive and negative controls. Samples with altered or positive findings were sequenced by Sanger (Macrogen, South Korea). Gene fusions were studied by reverse

| Table 1 Characteristics of thirty patients with a diagnosis of NIFTP |
|----------------------|--------------|----------------|
| Age at diagnosis (years) | 53 (44.7–61.2) |
| Gender (female/male) | 25/5 |
| Categories of TBSRTC | |
| I | 0 (0%) |
| II | 2 (7%) |
| III | 2 (7%) |
| IV | 1 (3%) |
| V | 10 (33%) |
| VI | 10 (33%) |
| Incidental finding | 5 (17%) |
| Tumor >4 cm | 3 (10%) |
| Metastatic lymph nodes | 0% |
| Distant metastases | 0% |
| Tumor diameter (mm) | 14.5 (6.7–22.2) |
| Follow-up (months) | 37 (22.5–82.5) |

Categorical values were presented as percentages and numerical values as median (25th–75th percentile)

TBSRTC The Bethesda system for reporting thyroid cytology
transcription followed by RT PCR and visualized in agarose gel.

Statistical analysis

Categorical values were presented as percentages and numerical values as median (25–75th percentile).

Results

Out of 2677 PTC patients, 456 (17%) were FVPTC and 30 fulfilled diagnostic criteria for NIFTP (1.12% of all PTC and 6.57% of all FVPTC).

Table 1 describes the clinical characteristics of the study population. Fine needle thyroid aspiration (FNA) was performed before surgery in 25 patients (83%): in 10 patients results were classified as suspicious for malignancy (Category V, according to the Bethesda system for reporting cytology), in 10 as malignant (Category VI), in 1 patient as follicular neoplasm or suspicious for follicular neoplasm (category IV), 2 as atypia of undetermined significance or follicular lesion of undetermined significance (category III), and 2 benign (category II).

All patients underwent total thyroidectomy, and 15 (50%) were treated with radioiodine with a median dose of 100 mCi $^{131}$I. No metastatic lymph nodes or distant metastases were found at diagnosis.

After a median follow-up of 37 months (22.5–82.5), 25 patients (84%) showed no evidence of disease, one patient (3%) with initially undetectable anti-thyroglobulin antibodies developed detectable anti-thyroglobulin antibodies during follow-up and data was missing for the remaining 4 (13%). During follow-up, none of the patients had a structural incomplete response nor required additional therapies.

| Table 2 Molecular alterations found in 19 patients diagnosed with NIFTP* |
|-------------------------------------------------|
| Patients with molecular alterations |
| PAX8/PPAR-Gamma fusions | 0 |
| Exon 2 and 3 K-RAS mutations | 0 |
| Exon 2 N-RAS mutation | 0 |
| Exon 3 N-RAS Q61K mutation (c.181C>A) | 2 |
| Exon 2 H-RAS mutation | 0 |
| Exon 3 H-RAS Q61R mutation (c.182A>G) | 2 |
| BRAF K601E mutation | 1 |

*NIFTP Non-invasive follicular neoplasm with papillary-like nuclear features

Genetic studies were performed in 19 tumors (63%) and molecular alteration were found in only 5: in 2/19 an exon 3 N-RAS Q61K (c.181C>A) was found and in 2/19 a mutation of exon 3 H-RAS Q61R (c.182A>G). BRAF K601E mutation was found in 1 patient (Table 2). No RET/PTC1 and PAX8/PPAR-Gamma fusions were detected (Fig. 1).

Discussion

Encapsulated non-invasive follicular variant of PTC was reclassified as NIFTP in 2016 [1], and was included in the WHO Classification of Tumors of Endocrine Organs in 2017 [7] as a separate entity, acknowledging its very low malignant potential. However, Ferris et al. [8] recommend considering NIFTP as a preneoplastic lesion. Therefore, and considering that the reclassification is a recent event, strict follow-up is endorsed until further evidence is gathered.

Prevalence of NIFTP in our series was 1.12%, (30/2677), thus being among the lowest reported. Similar findings were found in Korea (0.18% (2/1411 PTC), Japan (0.5% (54/10176) and Canada (2.1% (102/4790) [9–11]. In a multi-institutional series from Southern Europe, the rate was 5.2%, but was highly variable in neighboring institutions, ranging from 0 to 12.1%, suggesting pathologist’s interpretation of nuclear alterations as the main cause of these differences [12]. A meta-analysis including seven series showed that the incidence of NIFTP was 1.6% in different Asian populations. This is significantly lower than the incidence found in non-Asian series, which can be as high as 15% [13]. Dissimilarities may be due to environmental and ethnic differences, as well as the thorough examination and strict criteria for diagnosing NIFTP that the samples in our series were submitted to. Also, in some countries, fear of malpractice claims can modify the histological thresholds, leading many pathologists to diagnose malignancy in equivocal lesions [14].

Although widespread adoption of the new NIFTP terminology was anticipated, reports of NIFTP on cancer registries failed so far to confirm this. Kitahara et al. [15] in 2017 informed that the observed number of NIFTPs recorded in SEER-18 accounted for only 1.3% of the number of total PTCs, much lower than the estimated proportion predicted by Nikiforov et al. (18.6%). Furthermore, a recent study including 3368 pathology reports from six countries found that the prevalence of NIFTP among PTC cases was 4.8%. No substantial changes in the frequency of diagnosis of NIFTP were found from 2016 to 2019 [16].

Regarding cytological evaluation of NIFTP, it was suggested that there are certain characteristics, such as hypercellularity, sheet-like architecture, follicular pattern, follicular microarchitecture and nuclear score that
point towards the diagnosis [17, 18]. However, in order to establish an accurate diagnosis of NIFTP, the indemnity of the tumor capsule needs to be fully assessed and lympho-vascular invasion should be ruled out, and this cannot be estimated exclusively on the information yielded by FNA [19]. Additionally, even if psamomma bodies and papillae are exclusive of PTC, other nuclear features are shared between NIFTP and PTC [7, 18, 20, 21]. In our series, only 9% of the cases had cytologic diagnosis corresponding to the categories III and IV of the BSRC. This is in contrast with other results, showing that the prevalence of these categories may reach to 58% [20]. The impact of changes in the predictive value for malignancy of ultrasonography, cytology, molecular tests or even fluorodeoxyglucose positron emission tomography (FDG-PET) depend on the prevalence of NIFTP in the population [22]. However, Katsakhyan et al. [24] did not find significant changes in the number of total or partial thyroidectomies performed as initial surgeries comparing a pre- to a post-NIFTP cohort. Perhaps more time is needed to show changes, as a significant increase in the rate of hemithyroidectomies was found when comparing surgical treatment of thyroid cancer before or after the release of the 2015 American Thyroid Association Guidelines [25].

As for follow-up, since NIFTP was only recently established as a diagnostic entity, it was suggested that an occasional neck ultrasound and annual measurements of thyroglobulin and anti-thyroglobulin antibodies should be performed until more clinical experience is obtained [8]. In contrast, Rosario argues that if patients with NIFTP continue to be followed up like those with low risk PTC, the practical impact promoted by these changes would have been minimal or none [26].

Molecular biology studies were performed in 19 cases (63%). RAS mutations were the most frequent finding and were identified in 4 tumors (13%). This is in coincidence with other studies, in which overall prevalence of RAS mutations ranges from 10 to 67% [1, 27, 28]. This genetic profile is similar to the one found in other follicular lesions (such as PVCPT, follicular adenoma and follicular
carcinoma), and differs from the usual molecular findings in classic PTC, further warranting the reclassification of NIFTP as a different entity. In our series, HRAS and NRAS mutations were equally frequent (6.5% each), in contrast with other reports, in which HRAS mutations comprise between 25 and 50% of cases [1, 27–34] being NRAS mutations the most usual [27, 28, 35, 36].

The original diagnostic criteria for NIFTP were proposed in 2016 [1], and then modified in 2018 [6] stating that the presence of any true papillary structure would rule out the diagnosis of NIFTP. In addition, if molecular testing (which is not mandatory) is performed, the presence of high-grade mutations, such as TERT, BRAF V600E, or RET/PTC rearrangements would exclude the diagnosis of NIFTP. This item raises the practical question of whether NIFTP can be diagnosed without molecular biology techniques, which are not routinely available in Argentina.

Additionally, an accurate differential diagnosis of NIFTP from encapsulated FVPTC requires, besides routine BRAF mutation testing, a complete assessment of the tumor (and not only the capsule) to rule out the presence of papillae [37]. This places higher demands on the pathologists (both in terms of time and expertise), and also may lead to further diagnostic confusion and increasing costs (due to mandatory molecular studies). The benefits are therefore unclear, as both entities share a similar clinical behavior. Further studies with longer follow-up are needed to elucidate these questions.

In conclusion, NIFTP prevalence in this series was among the lowest reported. Excellent response to initial treatment confirms the indolent behavior of these neoplasms, which will probably lead to a more conservative management, avoiding unnecessary expenses for the health care system, and reducing emotional distress for patients with this diagnosis. Molecular findings differ from other series, which may be related to stringent criteria for diagnosing NIFTP and/or to environmental or ethnic features of our population.

Acknowledgements We thank the members of the Thyroid Department of Sociedad Argentina de Endocrinología y Metabolismo: Abadovich Marcos, Abelleira Erika, Alcaraz Graciela, Bielski Leila, Brenta Gabriela, Castro Jozami Lorena, Cavallo Andrea, Corino Mirta, Faure Eduardo, Frascaroli Genoveva, Gauna Alicia, Guerra Jorgelina, Gutierrez Silvia, Ilera Verónica, Iorcansky Sonia, Löwenstein Alicia, Martínez Maria, Moldes Sofía, Negueruela María, Oneto Adriana, Orlandi Ana, Parisi Carina, Reyes Adriana, Rosembit Cinthia, Russo Picasso María, Sala Mónica, Sartorio Gerardo, Schnitman Marta, Silva Croome María, Sklate Rosana, Storani Maria, Vazquez Adriana, Zund Santiago, Zunino Anaabela.

Ethical approval The study was approved by the Institutional Review Board.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Y.E. Nikiforov, R.R. Seethala, G. Tallini, Z.W. Baloch, F. Basolo, L.D. Thompson, J.A. Barletta, B.M. Wenig, A. Al Ghuzlan, K. Kakudo, T.J. Giordano, V.A. Alves, E. Khanaﬁshar, S.L. Asa, A.K. El-Nagger, W.E. Gooding, S.P. Hodak, R.V. Lloyd, G. Maytal, O. Mete, M.N. Nikiforova, V. Nosé, M. Papotti, D.N. Poller, P.M. Sadow, A.S. Tischler, R.M. Tuttle, K.B. Wall, V.A. LiVolsi, G.W. Randolph, R.A. Ghossein. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2(8), 1023–1029 (2016). https://doi.org/10.1001/jamaoncol.2016.0386

2. K.T. Chem, J. Rosai. Follicular variant of thyroid papillary carcinoma: a clinicopathologic study of six cases. Am. J. Surg. Pathol. 2, 123–130 (1977). https://doi.org/10.1097/00000478-197706000-00003

3. J. Liu, B. Singh, G. Tallini, D.L. Carlson, N. Katabi, A. Shaha, R.M. Tuttle, R.A. Ghossein. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 15, 1255–1264 (2006). https://doi.org/10.1002/cncr.22138

4. C. Lupi, R. Giannini, C. Ugolini, A. Proietti, P. Berti, M. Minuto, G. Materazzi, R. Elisei, M. Santoro, P. Miccolo, F. Basolo. Association of BRAF V600E mutation with poor clinical-pathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 92(11), 4085–4090 (2007). https://doi.org/10.1210/jc.2007-1179

5. V.A. LiVolsi, K. Kakudo, V.A. LiVolsi, R.V. Lloyd, Y.E. Nikiforov, V. Nosé, M. Papotti, L.D. Thompson. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): achieving better agreement by refining diagnostic criteria. Clinics. 73, e576 (2018). https://doi.org/10.6061/clinics/2018/e576

6. Y.E. Nikiforov, Z.W. Baloch, S.P. Hodak, T.J. Giordano, R.V. Lloyd, R.R. Seethala, B.M. Wenig. Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillary like nuclear features. JAMA Oncol. 4, 1125–1126 (2018). https://doi.org/10.1001/jamaoncol.2018.1446

7. R.I. Lloyd, R.Y. Osamura, G. Klöppel, J. Rosai. WHO Classification of Tumours of Endocrine Organs WHO/IARC Classification of Tumours, 4th edn, vol 10 (International Agency for research on Cancer (IARC), Lyon, France, 2017)

8. R.L. Ferris, Y.E. Nikiforov, D. Terris, R.R. Seethala, J.A. Ridge, P. Angelos, Q.Y. Duh, R. Wong, M.M. Sabra, J.A. Fagin, B. McIver, V.J. Bernet, R.M. Harrell, N. Busaidy, E.S. Cibas, W.C. Faquin, P. Sadow, Z. Baloch, M. Shindo, L. Orloff, L. Davies, G.W. Randolph. AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Head. Neck. 40(9), 1881–1888 (2018). https://doi.org/10.1002/hed.25141

9. H. Kim, B. Kim, Y.K. Kim, J.M. Kim, SY Oh, E.H. Kim, M.J. Lee, J.H. Kim, Y.K. Jeon, S.S. Kim, B.J. Lee, Y.K. Kim, I.J. Kim. Prevalence of BRAFV600E mutation in follicular variant of papillary thyroid carcinoma and non-invasive follicular tumor with papillary-like nuclear features (NIFTP) in a BRAFV600E prevalent area. J. Korean Med Sci. 33(27), e75 (2018). https://doi.org/10.3346/jkms.2018.33.e75

Compliance with ethical standards

Conflict of interest The authors declare no competing interests.
Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a prospective study. Thyroid 26(1), 1–133 (2016). https://doi.org/10.1089/thy.2015.0020

P.W. Rosario, G.F. Mourão, Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); a review for clinicians. Endocr. Relat. Cancer 26, R259–R266 (2019). https://doi.org/10.1530/ERC-19-0048

M. Kim, M.J. Jeon, H.S. Oh, S. Park, T.Y. Kim, Y.K. Shong, W.B. Kim, K. Kim, W.G. Kim, D.E. Song, BRAF and RAS mutational status in noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): an institutional experience. Endocr. Pathol. 31, 174–181 (2020). https://doi.org/10.1007/s12022-020-09614-5

T.M. Ullmann, K.D. Gray, D. Stefanova, J. Limberg, J.L. Buicko, B. Finnerty, R. Zarnegar, T.J. Fahey 3rd, T. Beninato, The 2015 American Thyroid Association guidelines are associated with an increasing rate of hemithyroidectomy for thyroid cancer. Surgery 166, 349–355 (2019). https://doi.org/10.1016/j.surg.2019.03.002

V. Baloch, W.J. LiVolsi, Z.W. Baloch, Practice paradigms before and after introduction of the diagnosis-noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): a multicentre retrospective Southern European study with prolonged follow-up. Endocrine 73, 585–605 (2021). https://doi.org/10.1007/s12020-021-02610-7

M. Paja, C. Zafón, C. Iglesias, A. Ugalde, J.M. Cameselle-Teot, E.S. Cibas, N.I. Lindeman, J.F. Krane, Preoperative X. Quian, T.J. Wieczorek, C.A. French, L.A. Teot, P.M. Sadow, Trends in diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features and total thyroidectomies for patients with papillary thyroid neoplasms. JAMA Otolaryngol. Head Neck Surg. (2021).https://doi.org/10.1001/jamaoto.2021.133 (2021). https://doi.org/10.1007/s12022-018-9515-x

F. Maletta, F. Massa, L. Torregrossa, E. Duregon, G.P. Casadei, F. Basolo, G. Talli, M. Volante, Y.E. Nikiforov, M. Papotti, Cytological features of “non-invasive follicular neoplasm with papillary-like nuclear features” and their correlation with tumor histology. Hum. Pathol. 54, 134–142 (2016). https://doi.org/10.1016/j.humpath.2016.03.014

B. Xu, R.A. Ghossein, Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): an update. Head Neck Pathol. 14(2), 303–310 (2020). https://doi.org/10.1007/s12105-019-01124-z

W.C. Faquin, L.Q. Wong, A.H. Afrogehe, S.Z. Ali, J.A. Bishop, M. Bongiovanni, M.P. Pusztaszeri, C.J. VandenBussche, J. Gourmaud, L.J. Vaickus, Z.W. Baloch, Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. Cancer Cytopathol 124(3), 181–187 (2016). https://doi.org/10.1002/cncy.21631

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1), 1–133 (2016). https://doi.org/10.1089/thy.2015.0020
noninvasive follicular thyroid neoplasms with papillary-like nuclear features compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas. Mod. Pathol. 30, 39–51 (2017). https://doi.org/10.1038/modpathol.2016.157

32. N.P. Ohori, J. Wolfe, S.E. Carty, L. Yip, S.O. LeBeau, A.N. Berg, K.E. Schoedel, Y.E. Nikiforov, R.R. Seethala, The influence of the noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) resection diagnosis on the false-positive thyroid cytology rate relates to quality assurance thresholds and the application of NIFTP criteria. Cancer Cytopathol. 125, 692–700 (2017). https://doi.org/10.1002/cncy.21892

33. U. Cho, O. Mete, M.H. Kim, J.S. Bae, C.K. Jung, Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features. Mod. Pathol. 30, 810–825 (2017). https://doi.org/10.1038/modpathol.2017.9

34. R. Giannini, C. Ugolini, A.M. Poma, M. Urpi, C. Niccolì, R. Elisei, M. Chiarugi, P. Vitti, P. Miccoli, F. Basolo, Identification of two distinct molecular subtypes of non-invasive follicular neoplasm with papillary-like nuclear features by digital RNA counting. Thyroid 27, 1267–1276 (2017). https://doi.org/10.1089/thy.2016.0605

35. N. George, A. Agarwal, N. Kumari, S. Agarwal, N. Krishnani, S.K. Gupta, Molecular profiling of follicular variant of papillary thyroid cancer reveals low-risk noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a paradigm shift to reduce aggressive treatment of indolent tumors. Indian J. Endocrinol. Metab. 22, 339–346 (2018). https://doi.org/10.4103/ijem.IJEM_86_18

36. T.C. Brandler, C.Z. Liu, M. Cho, F. Zhou, J. Cangiarella, M. Yee-Chang, Y. Shi, A. Simsir, W. Sun, Does noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) have a unique molecular profile? Am. J. Clin. Pathol. 150, 451–460 (2018). https://doi.org/10.1093/ajcp/aqy075

37. C. Liu, The phrase NIFTP accentuates, rather than resolves, the current issues with thyroid neoplasm classification. Hum. Pathol. 79, 222 (2018). https://doi.org/10.1016/j.humpath.2018.02.030